SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001012168-98-000029
Filing Date
1998-04-23
Accepted
1998-04-23 00:00:00
Documents
1
Group Members
ANDREW B. FREMDERDAVID I. COHENENRIQUE H. BOILINIFARALLON CAPITAL INSTITUTIONAL PARTNERS II, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS III, L.P.FARALLON CAPITAL INSTITUTIONAL PARTNERS, L.P.FARALLON CAPITAL MANAGEMENT LLC /ADVFARALL
SROs
NASD

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13D SC 13D/A 84384
  Complete submission text file 0001012168-98-000029.txt   87088
Mailing Address 9393 TOWNE CENTRE DRIVE SAN DIEGO CA 92121
Business Address 9393 TOWNE CENTRE DR STE 100 SAN DIEGO CA 92121 6195353900
LIGAND PHARMACEUTICALS INC (Subject) CIK: 0000886163 (see all company filings)

IRS No.: 770160744 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D/A | Act: 34 | File No.: 005-43329 | Film No.: 98599573
SIC: 2834 Pharmaceutical Preparations

Mailing Address ONE MARITIME PLAZA SUITE 1325 SAN FRANCISCO CA 94111
Business Address ONE MARITIME PLZ STE 1325 SAN FRANCISCO CA 94111 4154212132
FARALLON CAPITAL MANAGEMENT LLC /ADV (Filed by) CIK: 0001012168 (see all company filings)

IRS No.: 943240279 | State of Incorp.: DE | Fiscal Year End: 1231